Cancer Science

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ENAD Ayiou Dometiou FC, Radiation, University, Therapy, Function, Bio, Cancer Research UK, University college, Research fellow, Antibody, Radiation therapy, Cancer Science, University of Glasgow, MRI, Date, Primary tumor, Transgene, Patient, Monochorionic twins, Master of Science, School, Chemokine, Cytokine, Society, Vaccine, Medical imaging, Safety, Chemoradiotherapy

In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.

Key Points: 
  • In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.
  • Further, hexon staining of patient samples suggested EnAd localization in both the primary tumor and in metastatic sites.
  • “These data are compelling given the higher-than-expected pCR/cCR rate, and the low adverse event rate highlights the ability to deliver the oncolytic virus concurrently with chemoradiation.
  • ET
    Presenter: Dr Séan M. O’Cathail, MSc DPhil MRCPI FRCP FRCR, Senior Research Fellow, School of Cancer Sciences, University of Glasgow

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Retrieved on: 
Friday, September 1, 2023
AME Publishing Company, Lead, University, Medivir, Clifton Springs Hospital & Clinic, Cancer, DRS, Reig, Oncology, BCLC, Research, CMO, Cancer Science, Defence Scientific Advisory Council, ECMC, University of Glasgow, Liver cancer, Patient, School, Dr. Evan Alexander Erwin House, Webcast, Hospital, HCC, Lenvatinib, Disease, Pharmaceutical industry, Medical device, Beatson West of Scotland Cancer Centre

The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.

Key Points: 
  • The webcast will feature presentations by Dr. Jeff Evans, Beatson West of Scotland Cancer Center, Glasgow, UK, who will discuss the current treatment landscape and unmet medical need in treating patients with HCC.
  • He will be joined by Dr. Maria Reig, Liver Cancer Unit, Hospital Clínic BCLC group, Villarroel, Barcelona, Spain, who will discuss how HCC is different from many other tumor types and its unique treatment challenges.
  • Both Drs are investigators in the phase 1b/2a study with fostrox in combination with Lenvima and will also share their perspectives from the ongoing study.
  • The webcast will be streamed via a link on the website: www.medivir.com/investors/presentations The presentation will be available on Medivir´s website after the webcast.

Kanazawa University research: Cancer biology: Some cancer cells can lose their capability to migrate

Retrieved on: 
Tuesday, January 17, 2023
Gene, B cell, Cell, Liver, Cancer, Growth, Metastasis, Mouse, Kanazawa University, Research, Neoplasm, Vaccine, Cancer Science

KANAZAWA, Japan, Jan. 17, 2023 /PRNewswire/ -- In a study recently published in Cancer Science, researchers from Kanazawa University show how some intestinal cancer cells lose their ability to spread as they divide and can be eliminated as the cancer grows.

Key Points: 
  • KANAZAWA, Japan, Jan. 17, 2023 /PRNewswire/ -- In a study recently published in Cancer Science, researchers from Kanazawa University show how some intestinal cancer cells lose their ability to spread as they divide and can be eliminated as the cancer grows.
  • However, the role of negative selection—the process of foregoing cells with disadvantageous mutations—has not been clearly linked with cancer.
  • Now, a team led by Masanobu Oshima at Kanazawa University has revealed the potential involvement of negative selection in intestinal tumors.
  • This study establishes that certain cancer cells lose their migratory properties and are, thus, eliminated in order for tumor tissues to grow.

Kanazawa University research: Cancer biology: Some cancer cells can lose their capability to migrate

Retrieved on: 
Tuesday, January 17, 2023
Gene, B cell, Cell, Liver, Cancer, Growth, Metastasis, Mouse, Kanazawa University, Research, Neoplasm, Vaccine, Cancer Science

KANAZAWA, Japan, Jan. 17, 2023 /PRNewswire/ -- In a study recently published in Cancer Science, researchers from Kanazawa University show how some intestinal cancer cells lose their ability to spread as they divide and can be eliminated as the cancer grows.

Key Points: 
  • KANAZAWA, Japan, Jan. 17, 2023 /PRNewswire/ -- In a study recently published in Cancer Science, researchers from Kanazawa University show how some intestinal cancer cells lose their ability to spread as they divide and can be eliminated as the cancer grows.
  • However, the role of negative selection—the process of foregoing cells with disadvantageous mutations—has not been clearly linked with cancer.
  • Now, a team led by Masanobu Oshima at Kanazawa University has revealed the potential involvement of negative selection in intestinal tumors.
  • This study establishes that certain cancer cells lose their migratory properties and are, thus, eliminated in order for tumor tissues to grow.

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021
Netherlands Cancer Institute, Biology, Dutch Cancer Society, MAP2K4, MAP, All European Academies, Colorectal cancer, Diagnosis, KRAS, Translational research, News, MEK, Valorisation, MKK4, DGAP, Cancer research, Research, Cancer Science, Liver regeneration, Quality of life, Justicia oncodes, Hepatocyte, Patient, Economy, Novo Holdings A/S, Cancer, Pharmaceutical industry, HepaRegeniX GmbH -, the Oncode Institute, Utrecht, HEPAREGENIX GMBH -, THE ONCODE INSTITUTE, UTRECHT

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Retrieved on: 
Wednesday, October 13, 2021
Cancer Science, Death, Cell, Technology, Professor, Securities Exchange Act of 1934, Drug combination, Diagnosis, Terminology, Genome, Cancer, NKI, Valorisation, Dutch Cancer Society, Netherlands Cancer Institute, PP2A, BRAF, Nature, Neoplasm, Securities Act of 1933, Marketing, FDA, Drug Quality and Security Act, Economy, Patient, Biology, GLOBE, U.S. Securities and Exchange Commission, Toxicity, Company, European Academy of Allergy and Clinical Immunology, EGFR, CEO, Research, CA, Quality of life, Justicia oncodes, Liver cancer, Pharmaceutical industry

Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.

Key Points: 
  • Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.
  • Professor Bernards commented, We are excited to work with Lixte to identify the most powerful drug combinations of LB-100 for cancer therapy.
  • Our unbiased genetic approach to identify synthetic lethal drug targets of LB-100 has proven its utility in our previous studies.
  • www.lixte.com
    About the Netherlands Cancer Institute, Amsterdam
    The Netherlands Cancer Institute , founded in 1913, is among the worlds best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Immunicom Presents Promising Preliminary Data from Immunopheresis® Studies in Late-Stage Cancer Patients at JCA-AACR 2021

Retrieved on: 
Tuesday, September 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Education, Association, American Association, Immune system, Patient, Renal cell carcinoma, Japanese Cancer Association, Large-cell lung carcinoma, Jagiellonian University, Degenerative disease, Research, AACR, Science, American Association for Cancer Research, Antibody, ISO, Conference, Medicine, Toxicity, NSCLC, Radiation, Diagnosis, CE marking, Cancer, Principal investigator, Immunotherapy, Food, Bristol Myers Squibb, FDA, Protein, Japanese Association of Medical Sciences, Cytokine, Certification, Quality of life, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TNBC, Technology, Doctor of Philosophy, Risk, Clinical trial, Sheba Medical Center, JCA, Cancer Science, Multimedia, Pharmaceutical industry, Vaccine, Medical device, Immunicom, JCA and AACR, IMMUNICOM, JCA AND AACR

Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.

Key Points: 
  • Immunicom, Inc ., a clinical-stage biotechnology company pioneering subtractive advanced cancer therapies, presented promising preliminary data from trials investigating Immunopheresis therapy for metastatic, refractory, solid tumor cancer patients who previously failed multiple lines of therapy.
  • Immunicoms ongoing clinical trials are in the most difficult to treat, late-stage cancer patients.
  • Immunicoms novel Immunopheresis therapy uses its proprietary subtractive LW-02 column to selectively remove immune-suppressive cytokines produced by cancer tumors.
  • Standard cancer treatments are surgery, radiation or those that typically require the infusion of drugs, antibodies or proteins into the patient.

Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science

Retrieved on: 
Friday, August 13, 2021
Doxorubicin, Triple-negative breast cancer, NASDAQ, Agreement Respecting a New Relationship Between the Cree Nation and the Government of Quebec, MDR1, Clinical trial, Neutropenia, SEDAR, Docetaxel, Canadian Cancer Society, Cancer Science, PDC, Company, TSX, Tumor microenvironment, Senior, Survival, Cancer, Christian democracy, COVID-19, GLOBE, TNBC, Research, Ovary, FDA, Toxicity, Health, Skin, Mission statement, Consortium, Humanitarian use licenses, Lung, SORT1, Safety, Forward-looking statement, EDGAR, Peptide, Pharmaceutical industry, Fine chemical

The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

Key Points: 
  • The article is titled TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
  • Theratechnologies is currently developing a platform of new proprietary peptides for cancer drug development targeting SORT1 receptors called SORT1+ TechnologyTM.
  • It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.

Repositive Launches World-Leading Directory of Preclinical Cancer Models on Science Exchange

Retrieved on: 
Tuesday, October 22, 2019
Oncology, Data management, Health, Technology, Software, Pharmaceutical, Biotechnology, Cancer Science, Academic journals, Periodicals, Publications, Repositive, Science Exchange

Repositive today announced that its Cancer Models Directory, containing over 5,300 preclinical cancer models, is available on Science Exchange , the widely used technology platform for outsourced R&D.

Key Points: 
  • Repositive today announced that its Cancer Models Directory, containing over 5,300 preclinical cancer models, is available on Science Exchange , the widely used technology platform for outsourced R&D.
  • This collaboration further broadens global access to Repositives world-leading directory of preclinical cancer models and comprehensive Cancer Models Scout service, which includes expert bioinformatic analysis to ensure the right models are identified for every customers research project.
  • Repositives Cancer Models Directory catalogues the metadata for over 5,300 PDX and CDX models, syngeneic and humanized mouse models, GEMMs, cell lines and organoids from specialist oncology CROs around the world.
  • Were delighted to be collaborating with Science Exchange to increase access to our Cancer Models Directory and specialist Cancer Models Scout service amongst the translational oncology community, said Fiona Nielsen, CEO of Repositive.